Premium
Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell‐Mediated and Humoral Immunity Against Influenza Virus
Author(s) -
Lim JongWoo,
Na Woonsung,
Kim HyunOuk,
Yeom Minjoo,
Park Geunseon,
Kang Aram,
Chun Haejin,
Park Chaewon,
Oh Seungseok,
Le Van Phan,
Jeong Hyoung Hwa,
Song Daesub,
Haam Seungjoo
Publication year - 2019
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201800953
Subject(s) - adjuvant , humoral immunity , immunity , virology , virus , cell mediated immunity , immunology , cellular immunity , influenza a virus , vaccination , immune system , influenza vaccine , medicine , microbiology and biotechnology , biology
Abstract Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene‐based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin‐12. Furthermore, co‐administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen‐specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.